PMID- 23299278
OWN - NLM
STAT- MEDLINE
DCOM- 20141015
LR  - 20211021
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 19
IP  - 1
DP  - 2014 Feb
TI  - Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy 
      for Japanese patients with castration-resistant prostate cancer: a retrospective 
      multi-institutional collaborative study.
PG  - 157-64
LID - 10.1007/s10147-012-0510-9 [doi]
AB  - BACKGROUND: The aim of this study was to retrospectively investigate clinical 
      outcomes by relative dose and dose intensity of docetaxel (DOC) as chemotherapy 
      for Japanese patients with castration-resistant prostate cancer (CRPC). METHODS: 
      A total of 145 CRPC patients who received more than 4 courses of DOC chemotherapy 
      at 14 hospitals between 2005 and 2011 were enrolled. Patients were divided into 
      two groups--those receiving a higher or lower dose (mg/m(2)) or dose intensity 
      (mg/m(2)/week). Differences between the groups regarding treatment outcomes and 
      adverse events (AEs) were determined. Additionally, prognostic factors predictive 
      of cancer-specific survival (CSS) in these patients were identified by both 
      univariate and multivariate analysis. RESULTS: The total patient group underwent 
      a mean of 11.2 +/- 7.4 DOC cycles, and the mean CSS after therapy was 15.6 +/- 10.1 
      months. The higher-dose group had a better prostate-specific antigen (PSA) 
      response than the lower-dose group. However, there was no significant difference 
      between the groups in prognosis after DOC chemotherapy. Leukopenia and 
      neutropenia were observed more frequently in the higher-dose group. Serum 
      biomarkers (including PSA, lactate dehydrogenase and alkaline phosphatase), 
      hemoglobin levels and presence of pain at initiation of chemotherapy, as well as 
      the PSA nadir level on first-line hormone therapy, all were significant 
      predictors of CSS. CONCLUSIONS: In the Japanese population, relatively low-dose 
      DOC chemotherapy had no deleterious effect on the CSS of CRPC patients, and a 
      lower incidence of AEs occurred, in spite of a diminished PSA response compared 
      with those receiving a higher dose.
FAU - Kamiya, Naoto
AU  - Kamiya N
AD  - Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, 
      Sakura, Chiba, 285-8741, Japan, naoto.kamiya@med.toho-u.ac.jp.
FAU - Suzuki, Hiroyoshi
AU  - Suzuki H
FAU - Ueda, Takeshi
AU  - Ueda T
FAU - Sato, Naohide
AU  - Sato N
FAU - Nakatsu, Hiroomi
AU  - Nakatsu H
FAU - Mikami, Kazuo
AU  - Mikami K
FAU - Sato, Nobuo
AU  - Sato N
FAU - Nomura, Kazushi
AU  - Nomura K
FAU - Akakura, Koichiro
AU  - Akakura K
FAU - Okano, Tatsuya
AU  - Okano T
FAU - Ooki, Takemasa
AU  - Ooki T
FAU - Naya, Yukio
AU  - Naya Y
FAU - Ota, Sho
AU  - Ota S
FAU - Masai, Motoyuki
AU  - Masai M
FAU - Ichikawa, Tomohiko
AU  - Ichikawa T
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130109
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Docetaxel
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance, Neoplasm
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms, Castration-Resistant/blood/*drug therapy/pathology
MH  - Retrospective Studies
MH  - Taxoids/*administration & dosage/adverse effects
MH  - Treatment Outcome
EDAT- 2013/01/10 06:00
MHDA- 2014/10/16 06:00
CRDT- 2013/01/10 06:00
PHST- 2012/08/14 00:00 [received]
PHST- 2012/12/09 00:00 [accepted]
PHST- 2013/01/10 06:00 [entrez]
PHST- 2013/01/10 06:00 [pubmed]
PHST- 2014/10/16 06:00 [medline]
AID - 10.1007/s10147-012-0510-9 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2014 Feb;19(1):157-64. doi: 10.1007/s10147-012-0510-9. Epub 
      2013 Jan 9.